Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro
The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisp...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2007-03, Vol.331 (2), p.224-227 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 227 |
---|---|
container_issue | 2 |
container_start_page | 224 |
container_title | International journal of pharmaceutics |
container_volume | 331 |
creator | HENGST, V OUSSOREN, C KISSEL, T STORM, G |
description | The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone. |
doi_str_mv | 10.1016/j.ijpharm.2006.11.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69004186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69004186</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-7e615121dcc22215ace3255db2c1639adf3fd0c74fcdc6fb6c26b7bfdd3594913</originalsourceid><addsrcrecordid>eNpF0MFO3DAQBmCralUW2kdo5Us5keCxYyc5tggKEhIXel5NbIf1KrFd24u6vfTVCWURh9FIo0__jIaQL8BqYKDOt7Xbxg2mueaMqRqgZrx5R1bQtaISTavekxUTbVdJaMUROc55yxbIQXwkR9CCZALUivz7EbylBdODLc4_0BiK9cXhRMNIB5fjJjyXx2KrF2UNnVwMOcw205hsxITFBX9G9XIO6mKT-_t_QtEbutmbFP7sMS6jYpdIb573OE8fXUnhE_kw4pTt50M_Ib-uLu8vrqvbu583F99vq8hFX6rWKpDAwWjNOQeJ2goupRm4BiV6NKMYDdNtM2qj1TgozdXQDqMxQvZND-KEnL7kxhR-72wu69llbacJvQ27vFY9Yw10aoFfD3A3zNasY3Izpv369WUL-HYAmDVOY0KvXX5znew6qZh4AhFogaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69004186</pqid></control><display><type>article</type><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</creator><creatorcontrib>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</creatorcontrib><description>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2006.11.024</identifier><identifier>PMID: 17150316</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject>Binding Sites ; Biological and medical sciences ; Bone and Bones - metabolism ; Bone Diseases - drug therapy ; Cholesterol Esters - metabolism ; Diphosphonates - metabolism ; Drug Delivery Systems - methods ; Durapatite - metabolism ; General pharmacology ; Liposomes - pharmacokinetics ; Liposomes - therapeutic use ; Medical sciences ; Particle Size ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments</subject><ispartof>International journal of pharmaceutics, 2007-03, Vol.331 (2), p.224-227</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18588560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17150316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HENGST, V</creatorcontrib><creatorcontrib>OUSSOREN, C</creatorcontrib><creatorcontrib>KISSEL, T</creatorcontrib><creatorcontrib>STORM, G</creatorcontrib><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</description><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Bone and Bones - metabolism</subject><subject>Bone Diseases - drug therapy</subject><subject>Cholesterol Esters - metabolism</subject><subject>Diphosphonates - metabolism</subject><subject>Drug Delivery Systems - methods</subject><subject>Durapatite - metabolism</subject><subject>General pharmacology</subject><subject>Liposomes - pharmacokinetics</subject><subject>Liposomes - therapeutic use</subject><subject>Medical sciences</subject><subject>Particle Size</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MFO3DAQBmCralUW2kdo5Us5keCxYyc5tggKEhIXel5NbIf1KrFd24u6vfTVCWURh9FIo0__jIaQL8BqYKDOt7Xbxg2mueaMqRqgZrx5R1bQtaISTavekxUTbVdJaMUROc55yxbIQXwkR9CCZALUivz7EbylBdODLc4_0BiK9cXhRMNIB5fjJjyXx2KrF2UNnVwMOcw205hsxITFBX9G9XIO6mKT-_t_QtEbutmbFP7sMS6jYpdIb573OE8fXUnhE_kw4pTt50M_Ib-uLu8vrqvbu583F99vq8hFX6rWKpDAwWjNOQeJ2goupRm4BiV6NKMYDdNtM2qj1TgozdXQDqMxQvZND-KEnL7kxhR-72wu69llbacJvQ27vFY9Yw10aoFfD3A3zNasY3Izpv369WUL-HYAmDVOY0KvXX5znew6qZh4AhFogaQ</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>HENGST, V</creator><creator>OUSSOREN, C</creator><creator>KISSEL, T</creator><creator>STORM, G</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</title><author>HENGST, V ; OUSSOREN, C ; KISSEL, T ; STORM, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-7e615121dcc22215ace3255db2c1639adf3fd0c74fcdc6fb6c26b7bfdd3594913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Bone and Bones - metabolism</topic><topic>Bone Diseases - drug therapy</topic><topic>Cholesterol Esters - metabolism</topic><topic>Diphosphonates - metabolism</topic><topic>Drug Delivery Systems - methods</topic><topic>Durapatite - metabolism</topic><topic>General pharmacology</topic><topic>Liposomes - pharmacokinetics</topic><topic>Liposomes - therapeutic use</topic><topic>Medical sciences</topic><topic>Particle Size</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HENGST, V</creatorcontrib><creatorcontrib>OUSSOREN, C</creatorcontrib><creatorcontrib>KISSEL, T</creatorcontrib><creatorcontrib>STORM, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HENGST, V</au><au>OUSSOREN, C</au><au>KISSEL, T</au><au>STORM, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>331</volume><issue>2</issue><spage>224</spage><epage>227</epage><pages>224-227</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>17150316</pmid><doi>10.1016/j.ijpharm.2006.11.024</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2007-03, Vol.331 (2), p.224-227 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_69004186 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Binding Sites Biological and medical sciences Bone and Bones - metabolism Bone Diseases - drug therapy Cholesterol Esters - metabolism Diphosphonates - metabolism Drug Delivery Systems - methods Durapatite - metabolism General pharmacology Liposomes - pharmacokinetics Liposomes - therapeutic use Medical sciences Particle Size Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments |
title | Bone targeting potential of bisphosphonate-targeted liposomes preparation, characterization and hydroxyapatite binding in vitro |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T10%3A07%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20targeting%20potential%20of%20bisphosphonate-targeted%20liposomes%20preparation,%20characterization%20and%20hydroxyapatite%20binding%20in%20vitro&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=HENGST,%20V&rft.date=2007-03-01&rft.volume=331&rft.issue=2&rft.spage=224&rft.epage=227&rft.pages=224-227&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2006.11.024&rft_dat=%3Cproquest_pubme%3E69004186%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69004186&rft_id=info:pmid/17150316&rfr_iscdi=true |